Y-Intercept (HK)’s Harmony Biosciences HRMY Stock Holding History

Y-Intercept (HK)’s Portfolio HRMY Stock Details HRMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$2.23M	Buy	56,815 +7,166	+14%	+$277K	0.05%	578
2026 Q2	$1.81M	Sell	49,649 -97,395	-66%	-$3.07M	0.04%	756
2026 Q1	$4.12M	Buy	147,044 +107,449	+271%	+$3.52M	0.08%	407
2025 Q4	$1.48M	Sell	39,595 -18,895	-32%	-$621K	0.03%	775
2025 Q3	$1.61M	Buy	58,490 +9,036	+18%	+$311K	0.04%	731
2025 Q2	$1.56M	Buy	+49,454	New	+$1.59M	0.04%	720
2025 Q1	–	Sell	-27,061	Closed	-$931K	–	1375
2024 Q4	$931K	Buy	27,061 +20,070	+287%	+$690K	0.06%	457
2024 Q3	$280K	Buy	+6,991	New	+$246K	0.02%	1047

Other funds holding HRMY

CX Institutional Auburn, Indiana $3.69B AUM 15.82% 1-Year Est. Return

Wedge Capital Management Charlotte, North Carolina $5.72B AUM 38.26% 1-Year Est. Return

CWA Asset Management Group Naples, Florida $3.39B AUM 25.16% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return

Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return

Polaris Capital Management Boston, Massachusetts $953M AUM 27.74% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return

State of Alaska Department of Revenue Juneau, Alaska $9.6B AUM 34.67% 1-Year Est. Return

Illumine Investment Management Poulsbo, Washington $144M AUM 33.61% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

Y-Intercept (HK)'s HRMY Position: Q3 2026 in Review

Y-Intercept (HK) increased its Harmony Biosciences (HRMY) stake by 14% in Q3 2026, buying an estimated $277K and bringing the position to 56,815 shares worth $2.23M. The position accounts for 0.05% of the portfolio, ranked #578.

Y-Intercept (HK) first reported a position in HRMY in Q3 2024 and has held it in 8 quarters since. The position peaked at $4.12M in Q1 2026. 40 funds tracked by Wall St. Rank hold HRMY as of Q3 2026.

Y-Intercept (HK) held 56,815 shares of Harmony Biosciences worth $2.23M as of Q3 2026.
Y-Intercept (HK) bought 7,166 Harmony Biosciences shares in Q3 2026, an estimated $277K.
Harmony Biosciences made up 0.05% of Y-Intercept (HK)'s portfolio in Q3 2026, its #578 holding.
Y-Intercept (HK) first reported a position in Harmony Biosciences in Q3 2024 and has held it in 8 quarters since.
Y-Intercept (HK)'s Harmony Biosciences position peaked at $4.12M in Q1 2026.
40 funds tracked by Wall St. Rank held Harmony Biosciences as of Q3 2026.

Based on Y-Intercept (HK)'s 13F filing for Q3 2026, filed 16 Oct 2026.